OBJECTIVES: To examine the success and complication rates in percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) caused by in-stent restenosis (ISR). BACKGROUND: PCI for in-stent total occlusive disease has traditionally been associated with low success rates. We sought to examine angiographic and procedural outcomes of patients who underwent CTO PCI due to ISR using the novel "hybrid" algorithm, and compare them with patients with de novo CTOs. METHODS: We examined 521 consecutive patients who underwent CTO PCI at five high-volume PCI centers in the United States using the "hybrid" approach. Clinical, angiographic, and procedural outcomes were compared between CTOs due to ISR and de novo CTOs. RESULTS: The target CTO was due to ISR in 57 of 521 patients (10.9%). Compared to patients with de novo CTOs, those with CTO due to ISR had higher frequency of diabetes (56.1% vs. 39.6%, P = 0.02) and less calcification (5.3% vs. 16.2%, P <0.001), but longer occlusion length [38 (29-55) vs. 30 (20-51), P = 0.04]. Technical success in the ISR and de novo group was 89.4% and 92.5% (P = 0.43), respectively; procedural success was 86.0% and 90.3% (P = 0.31), respectively; and the incidence of major adverse cardiac events was 3.5% and 2.2% (P = 0.63), respectively. CONCLUSIONS: Use of the "hybrid" approach to CTO PCI was associated with similarly high procedural success and similarly low major complication rates in patients with de novo and ISR CTOs.
OBJECTIVES: To examine the success and complication rates in percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) caused by in-stent restenosis (ISR). BACKGROUND: PCI for in-stent total occlusive disease has traditionally been associated with low success rates. We sought to examine angiographic and procedural outcomes of patients who underwent CTO PCI due to ISR using the novel "hybrid" algorithm, and compare them with patients with de novo CTOs. METHODS: We examined 521 consecutive patients who underwent CTO PCI at five high-volume PCI centers in the United States using the "hybrid" approach. Clinical, angiographic, and procedural outcomes were compared between CTOs due to ISR and de novo CTOs. RESULTS: The target CTO was due to ISR in 57 of 521 patients (10.9%). Compared to patients with de novo CTOs, those with CTO due to ISR had higher frequency of diabetes (56.1% vs. 39.6%, P = 0.02) and less calcification (5.3% vs. 16.2%, P <0.001), but longer occlusion length [38 (29-55) vs. 30 (20-51), P = 0.04]. Technical success in the ISR and de novo group was 89.4% and 92.5% (P = 0.43), respectively; procedural success was 86.0% and 90.3% (P = 0.31), respectively; and the incidence of major adverse cardiac events was 3.5% and 2.2% (P = 0.63), respectively. CONCLUSIONS: Use of the "hybrid" approach to CTO PCI was associated with similarly high procedural success and similarly low major complication rates in patients with de novo and ISR CTOs.
Authors: Emmanouil S Brilakis; J Aaron Grantham; Stéphane Rinfret; R Michael Wyman; M Nicholas Burke; Dimitri Karmpaliotis; Nicholas Lembo; Ashish Pershad; David E Kandzari; Christopher E Buller; Tony DeMartini; William L Lombardi; Craig A Thompson Journal: JACC Cardiovasc Interv Date: 2012-04 Impact factor: 11.195
Authors: Amr E Abbas; Stacy D Brewington; Simon R Dixon; Judith Boura; Cindy L Grines; William W O'Neill Journal: Am J Cardiol Date: 2005-06-15 Impact factor: 2.778
Authors: William M Wilson; Simon Walsh; Colm Hanratty; Julian Strange; Jonathan Hill; James Sapontis; James C Spratt Journal: EuroIntervention Date: 2014-03-20 Impact factor: 6.534
Authors: George D Dangas; Bimmer E Claessen; Adriano Caixeta; Elias A Sanidas; Gary S Mintz; Roxana Mehran Journal: J Am Coll Cardiol Date: 2010-11-30 Impact factor: 24.094
Authors: Emmanouil S Brilakis; Christopher Lichtenwalter; James A de Lemos; Michele Roesle; Owen Obel; Donald Haagen; Bilal Saeed; Chiranjeevi Gadiparthi; Joseph K Bissett; Rajesh Sachdeva; Vassilios V Voudris; Panagiotis Karyofillis; Biswajit Kar; James Rossen; Panayotis Fasseas; Peter Berger; Subhash Banerjee Journal: J Am Coll Cardiol Date: 2009-03-17 Impact factor: 24.094
Authors: Pinak B Shah; Donald E Cutlip; Jeffrey J Popma; Richard E Kuntz; Kalon K L Ho Journal: Catheter Cardiovasc Interv Date: 2003-11 Impact factor: 2.692
Authors: J R Martinez-Parachini; A Karatasakis; D Karmpaliotis; K Alaswad; F A Jaffer; R W Yeh; M Patel; J Bahadorani; A Doing; P-K Nguyen-Trong; B A Danek; J Karacsonyi; A Alame; B V Rangan; C A Thompson; S Banerjee; E S Brilakis Journal: Diabet Med Date: 2016-11-03 Impact factor: 4.359
Authors: Barbara A Danek; Aris Karatasakis; Dimitri Karmpaliotis; Khaldoon Alaswad; Farouc A Jaffer; Robert W Yeh; Mitul P Patel; John Bahadorani; William L Lombardi; R Michael Wyman; J Aaron Grantham; David E Kandzari; Nicholas J Lembo; Anthony H Doing; Catalin Toma; Jeffrey W Moses; Ajay J Kirtane; Ziad A Ali; Manish Parikh; Santiago Garcia; Phuong-Khanh Nguyen-Trong; Judit Karacsonyi; Aya J Alame; Pratik Kalsaria; Craig Thompson; Subhash Banerjee; Emmanouil S Brilakis Journal: Can J Cardiol Date: 2016-04-22 Impact factor: 5.223
Authors: Barbara Anna Danek; Aris Karatasakis; Dimitri Karmpaliotis; Khaldoon Alaswad; Robert W Yeh; Farouc A Jaffer; Mitul Patel; John Bahadorani; William L Lombardi; Michael R Wyman; J Aaron Grantham; Anthony Doing; Jeffrey W Moses; Ajay Kirtane; Manish Parikh; Ziad A Ali; Sanjog Kalra; David E Kandzari; Nicholas Lembo; Santiago Garcia; Bavana V Rangan; Craig A Thompson; Subhash Banerjee; Emmanouil S Brilakis Journal: Int J Cardiol Date: 2016-04-06 Impact factor: 4.164
Authors: Dimitri Karmpaliotis; Aris Karatasakis; Khaldoon Alaswad; Farouc A Jaffer; Robert W Yeh; R Michael Wyman; William L Lombardi; J Aaron Grantham; David E Kandzari; Nicholas J Lembo; Anthony Doing; Mitul Patel; John N Bahadorani; Jeffrey W Moses; Ajay J Kirtane; Manish Parikh; Ziad A Ali; Sanjog Kalra; Phuong-Khanh J Nguyen-Trong; Barbara A Danek; Judit Karacsonyi; Bavana V Rangan; Michele K Roesle; Craig A Thompson; Subhash Banerjee; Emmanouil S Brilakis Journal: Circ Cardiovasc Interv Date: 2016-06 Impact factor: 6.546
Authors: Judit Karacsonyi; Aris Karatasakis; Dimitri Karmpaliotis; Khaldoon Alaswad; Robert W Yeh; Farouc A Jaffer; Michael R Wyman; William L Lombardi; J Aaron Grantham; David E Kandzari; Nicholas Lembo; Jeffrey W Moses; Ajay J Kirtane; Manish A Parikh; Philip Green; Matthew Finn; Santiago Garcia; Anthony Doing; Mitul Patel; John Bahadorani; Jose Roberto Martinez Parachini; Erica Resendes; Bavana V Rangan; Imre Ungi; Craig A Thompson; Subhash Banerjee; Emmanouil S Brilakis Journal: Am J Cardiol Date: 2016-01-28 Impact factor: 2.778
Authors: Georgios Christopoulos; R Michael Wyman; Khaldoon Alaswad; Dimitri Karmpaliotis; William Lombardi; J Aaron Grantham; Robert W Yeh; Farouc A Jaffer; Daisha J Cipher; Bavana V Rangan; Georgios E Christakopoulos; Megan A Kypreos; Nicholas Lembo; David Kandzari; Santiago Garcia; Craig A Thompson; Subhash Banerjee; Emmanouil S Brilakis Journal: Circ Cardiovasc Interv Date: 2015-07 Impact factor: 6.546
Authors: Peter Tajti; Iosif Xenogiannis; Dimitris Karmpaliotis; Khaldoon Alaswad; Farouc A Jaffer; M Nicholas Burke; Imre Ungi; Emmanouil S Brilakis Journal: Curr Cardiol Rep Date: 2018-10-22 Impact factor: 2.931
Authors: Georgios E Christakopoulos; Dimitri Karmpaliotis; Khaldoon Alaswad; Robert W Yeh; Farouc A Jaffer; R Michael Wyman; William Lombardi; J Aaron Grantham; David A Kandzari; Nicholas Lembo; Jeffrey W Moses; Ajay Kirtane; Manish Parikh; Philip Green; Matthew Finn; Santiago Garcia; Anthony Doing; Mitul Patel; John Bahadorani; Georgios Christopoulos; Aris Karatasakis; Craig A Thompson; Subhash Banerjee; Emmanouil S Brilakis Journal: J Invasive Cardiol Date: 2016-07 Impact factor: 2.022